KEYNOTE-028, a multicohort phase Ib clinical study, enrolled 24 patients with PD-L1-positive advanced endometrial cancer with one patient distinguished by POLE mutation, one MSI, and the other patients undefined, all receiving pembrolizumab treatment. This evidence concerns the gene POLE and endometrial cancer.